Anteris Technologies Announces Results for the Second Quarter of 2026
Anteris announced Q2 2026 results highlighted by securing U.S. Medicare reimbursement for the pivotal PARADIGM Trial and initiating patient recruitment in the U.S. Net operating cash outflows were $20.8 million, driven primarily by clinical, regulatory, and manufacturing activities, while R&D expenses totaled $23.4 million.
Key figures
- Phase Of Trial
- global pivotal
- Rnd expenses
- $23.4 million
- Net operating cash outflows
- $20.8 million
- Paradigm trial target enrollment
- 1000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.